Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Metals Report
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
Steve Brozak is a top-ranked analyst in biotechnology according to the Starmine ranking system. He has been in the securities industry for more than 20 years, where he has held positions in sales, management, investment banking, and research analysis. He has been intimately involved in providing research on a number of companies. Brozak has a Bachelors of Arts and a Masters in Business Administration from Columbia University and is a retired lieutenant colonel in the United States Marine Corps.
Companies that Can Mend the Biotech Market: Stephen Brozak (4/11/13) Markets are not efficient—at least not in the short term. WBB Securities President Stephen Brozak admits to frustration when he sees small-cap companies with valuations that are disengaged from market realities. But Brozak's experience as a biotech investor, banker and analyst has taught him to be patient with these disconnection syndromes, and he now delights in prospects offered by select bargain-basement opportunities. In this interview with The Life Sciences Report, Brozak touches on 10 names that have been flying far below the radars of most investors.
Stephen Brozak: Changing the Way Money Is Made and Diseases Are Cured (1/24/13) Stephen Brozak doesn't mess around. He focuses on technologies poised to change the way medicine has been practiced for thousands of years. As president of WBB Securities, Brozak is talking to his clientele about revolutionary stem cell therapies that deal with disease in totally new ways. He's also bullish on new antibiotics—important innovations in a world facing a shortage of effective drugs and a potential crisis of catastrophic proportion. In this interview with The Life Sciences Report, Brozak talks up must-hear ideas that growth investors need to consider.
Make Friends with Companion Diagnostics to Bolster Your Biotech Portfolio: Stephen Brozak (5/24/12) Hitting just the right target and engineering cells to perform certain tasks will unlock the deep secrets of biology and change the entire paradigm of medicine, says WBB Securities President and Managing Partner Stephen Brozak. He is not picking the ultimate winners just yet, but he is playing stem cell and personalized medicine developers as a diversified portfolio, knowing that successes will overpower the also-rans. In this exclusive interview with The Life Sciences Report, Brozak shares names from his list of finalists.
"NBS has crossed the 50% enrollment mark on its PreSERVE-AMI phase 2 clinical trial; safety looks good and enrollment should be completed this year." (4/11/13) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >